Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Official Title

A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Summary:

The purpose of this study is to find out what effects new combinations of treatment will have this disease. In this clinical trial, the study treatment options currently are ibrutinib plus R-GDP, or R-GDP alone.

Trial Description

Primary Outcome:

  • Measure overall response rate
Secondary Outcome:
  • Number and severity of adverse events
  • Transplantation rate
  • Stem cell collection rate
  • Event free Survival Rate
  • Overall Survival
R-GDP has been used to treat many people with lymphoma. Ibrutinib has been shown to benefit people with certain types of lymphoma. They have not previously been given together. This research is being done to try to find new combinations of treatment that may be better for treating patients with this disease. It is not clear however if these treatments can offer better results than standard treatment. The standard or usual treatment of this disease is treatment with rituximab plus gemcitabine, dexamethasone, and cisplatin (R-GDP).

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society